Shareholders Approve New Equity Plans Authorizing Over 12 Million Additional Shares
MYGN sits 33% above its 52-week low of $3.53.
Summary
Myriad Genetics shareholders approved new equity incentive and employee stock purchase plans, authorizing the issuance of over 12.4 million additional shares, representing a potential dilution of approximately 13.2%.
Key Events · Corporate Governance and Compliance · MYGN
-
New Equity Incentive Plan Approved
Shareholders approved the 2026 Employee, Director and Consultant Equity Incentive Plan, authorizing the issuance of 8,463,567 shares, with a maximum potential of 8,659,575 shares.
-
Employee Stock Purchase Plan Share Increase
An amendment to the 2012 Employee Stock Purchase Plan was approved, increasing the number of shares authorized for issuance by an additional 4,000,000 shares.
-
Significant Potential Dilution
The combined authorization of new shares for both plans totals 12,463,567 shares, representing a potential dilution of approximately 13.2% based on the 94,443,029 shares outstanding as of April 8, 2026.
Analysis · MYGN · Life Sciences
Shareholders approved two new equity plans, significantly increasing the number of shares authorized for issuance. This includes an additional 4 million shares for the Employee Stock Purchase Plan and over 8.4 million shares for a new Equity Incentive Plan. This authorization represents a potential dilution of approximately 13.2% to existing shareholders, which is a substantial increase in the potential share count. This comes after the company recently reported a wider net loss for Q1 2026, making the potential dilution a key concern for investors.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MYGN was trading at $4.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $443M. The 52-week trading range was $3.53 to $8.59. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.